Table 1 Diagnostic, demographic, self-report, behavioral, and neuroimaging assessments
Diagnostic and demographic assessment | |
Diagnosis | MINI V6.0 [23] or the PRISM-5 |
History | Assessment of medication history and medication and therapy compliance |
Standard self-report scales | |
Substance use | Obsessive Compulsive Drug Use Scale (OCDUS) [21] |
Substance use | Customary Drinking and Drug Use Record (CDDR) [38] |
Substance use | Addiction Severity Index (ASI) [39] |
Substance use | Desire for Drug Questionnaire (DDQ) [21] |
Substance use | PROMIS Alcohol Use [40] |
Substance use | PROMIS Nicotine Dependence [41] |
Substance use | PROMIS Substance Use Severity [42] |
Mental health | PROMIS Adaptive Scales (depression, anxiety, and anger) [43] |
Mental health | Traumatic Events Questionnaire (TEQ) [44] |
Mental health | Difficulties in Emotion Regulation Scale (DERS) [45] |
Mental health | UPPS Impulsive Behavior Scale [46] |
Mental health | Behavioral Inhibition System/Behavioral Approach Scale (BIS/BAS) [47] |
Treatment engagement | Services Engagement Scale (SES) [2] |
Treatment engagement | Client Evaluation of Self and Treatment (CEST) Engagement [48] |
Feasibility/knowledge | Credibility/Expectancy Questionnaire (CEQ) [48] |
Feasibility/knowledge | Homework Rating Scale (HRS) [49] |
Feasibility/knowledge | Working Alliance Inventory (WAI) [50] |
Cognitive functions (subjective) | PROMIS Cog Abilities (PROMIS-CA) [22] |
Cognitive functions (subjective) | PROMIS Cog General (PROMIS-CG) [22] |
Behavioral assessment | |
Neuropsychological | NIH Toolbox Cognitive Assessment Battery [51] |
Neuropsychological | Iowa GamblingTask [52] |
Neuropsychological | Delayed Discounting [53] |
Neuropsychological | Emotional and Classic Go/NoGoTasks [54] |
Neuropsychological | Classic version of the go/no-go task [55] |
Neuroimaging assessments | |
Neuroimaging | T1-W sagittal MP-RAGE |
Neuroimaging | fMRI resting state |
Neuroimaging | fMRI monetary incentive delay [56] |
Neuroimaging | fMRI stop signal [57] |
Neuroimaging | fMRI drug cue reactivity [58] |
Neuroimaging | T2-W sagittal |
Neuroimaging | T2-W axial FLAIR |
Neuroimaging | Diffusion tensor imaging |
Laboratory assessments | |
Substance use | Urine drug test |
Biomarker assessment | Blood sample test |